Empowering Cell & Gene Therapies with Small Molecules
ChemT Biotechnology is an AI-driven biotech company developing a next-generation platform for cell and gene therapy. With our proprietary AI platform, we design and produce small molecules to significantly enhance the T cell therapy production, improving both yield and efficacy.
About
ChemT Biotechnology is an AI-driven biotech company focused on advancing the next generation of cell and gene therapies, such as CAR-T. We are dedicated to transforming immune cell therapy manufacturing. Our mission is to tackle the pressing challenges of production speed, cost and quality that currently limit the accessibility and effectiveness of these therapies.
Our first breakthrough product, CMT-01, is a small molecule that has shown superior results. With a 5-10x increase in T cell yield and significant enhancements in quality, CMT-01 has demonstrated both in vitro and in vivo efficacy. This innovation sets a new standard for T cell therapeutic manufacturing.
ChemT’s proprietary AI-Driven Drug Discovery (AIDD) platform is at the core of our innovation. Leveraging cutting-edge artificial intelligence, we are designing small molecules to modulate T cell therapies, aiming to make production more robust and scalable. By optimizing the yield and efficacy of T cell-based treatments, our platform offers a new approach to improving both the performance and accessibility of these life-changing therapies.
Our Team
Our team includes world-leading experts in molecular biology, chemistry, artificial intelligence and cell & gene therapy from several research institutions including the Harvard University, Stanford University, National University of Singapore, Karolinska Institute, and University College London, and with ample industry experiences from Johnson & Johnson, BeiGene, and AstraZeneca.
Ling Wu, PhD
President & Co-Founder
Jie Sun
CEO & Co-Founder
Hancheng Zhang, PhD
Strategic Partner
Science
Our flagship product, CMT-01, is a small molecule developed by ChemT to significantly boost T cell expansion by 5-10 times, while also enhancing the quality of T cell therapy products. This innovation offers a promising solution to some of the biggest challenges in manufacturing T cell therapeutics.
CMT-01 diverts T cell into a younger and healthier state via novel pathway. This opens a unique opportunity to explore an uncharted mechanism that could reshape our understanding of T cell biology.
Our vision extends beyond a single compound. We aim to replace traditional components like human serum and cytokines with small molecule products that create a chemically defined, consistent, and high-quality culture environment. This shift promises not only improved consistency and reliability but also greater scalability in T cell therapy manufacturing.
We leverage advanced AI models through our proprietary platform, enabling rapid identification and development of small molecules with targeted biological effects. Using this platform, we create precise screening models to discover targets whose modulation—whether through antagonism or agonism—enhances T cell expansion and improves product quality, potentially without the need for serum or cytokines.
Partner with ChemT
We are actively seeking collaboration with key stakeholders in T cell therapy, including research labs, biotech companies, pharmaceutical firms, and leading technology providers.